Top Markets
Coin of the day
Abliva AB (publ) Abliva AB (publ)

Abliva AB (publ)

ABLI
Kedudukan dalam Saham #22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Harga Saham
$0.04959193
Disegerakkan terakhir: 2025-03-17
Modal Pasaran
$79.94M
Perubahan (1 hari)
13.49%
Perubahan (1 tahun)
0.00%
Negara
SE
Perdagangan Abliva AB (publ) (ABLI)

Kategori

Sejarah dividen untuk Abliva AB (publ) (ABLI)
Abliva AB (publ) (simbol saham: ABLI) telah membuat sejumlah 0 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): 0.00
Hasil dividen (TTM): 0
Pembayaran dividen untuk Abliva AB (publ) (ABLI) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (diselaraskan untuk pemecahan saham) Ubah
Tidak cukup data untuk tarikh yang disediakan.
Senarai semua pembayaran dividen
Tahun Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pembayaran dividen untuk syarikat serupa atau pesaing
Syarikat Jumlah pembayaran dividen Negara
0.00%
US
0.00%
NL
0.00%
US
64.00%
AU
0.00%
CH